Rallybio

The Merger with Candid and the $505.5M Concurrent Financing are the decisive capital event: if they close as structured, Rallybio will have the funding to advance multiple programs without urgent dilutive raises. If true, shareholders get funded clinical development and optionality from Candid's TCE pipeline; if false, the company will face repeated dilutive financings or asset sales that compress equity value.

Monetization of legacy assets and milestone receipts (including the Recursion/ENPP1 sale) is a real and repeatable way Rallybio can create non‑dilutive value and fund R&D through contingent payments and CVR proceeds. If the company can continue to extract milestone and disposition proceeds, shareholders can benefit without immediate equity dilution; if such monetizations dry up or are smaller than expected, the company will be forced to dilute or cut programs.

Rallybio's operations are structurally cash‑consumptive (negative operating cash flow) and therefore require external capital, asset monetization, or a successful Merger to sustain program advancement. Sustained negative operating cash flow without offsetting financing forces dilution or program cuts; conversely, a reduction in burn or new non‑dilutive receipts preserves equity value.

Clinical validation of RLYB116 (and later programs) is the primary value driver because positive PK/PD and PoC would convert R&D programs into partnerable assets and milestone streams. If trials show RLYB116 is differentiated and reaches PoC, the company can obtain partnerships or higher valuations; if trials fail or are not differentiating, the asset's value collapses and monetization becomes unlikely.